- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05546931
Mobile Health Program for Rural Hypertension
August 14, 2023 updated by: Jared W Magnani, MD, MSc, University of Pittsburgh
Multilevel Mobile Health Program to Improve Rural Hypertension
Hypertension (HTN) is the leading modifiable cause of cardiovascular disease.
Rural individuals experience challenges of the rural health divide: geographic distance from providers, social isolation, limited social resources, and high rates of low health literacy.
This study evaluates a home-based blood pressure monitoring (HBPM) program that provides longitudinal health education, empathic guidance, monitoring, and adaptable patient-centered coaching to rural individuals.
Participants in this study will be randomized to receive (1) HBPM with the intervention; or (2) the control, consisting of HBPM and a smartphone with a general health application (WebMD).
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Hypertension (HTN) has increasing prevalence, is the leading cause of cardiovascular morbidity and mortality, and contributes significantly to health care utilization and costs.
Social determinants of health (SDOH) exacerbate patients' access to therapies, adherence, and health outcomes.
A robust literature demonstrates the effects of income, education, health literacy, and social resources on access to HTN treatment; medication adherence; and short- and long-term likelihood of clinical adversity.
In the U.S., geographic obstacles to care further complicate HTN treatment and outcomes for rural individuals.
This single-center, parallel group randomized clinical trial (RCT) evaluates a home-based blood pressure monitoring (HBPM) and cardiovascular mobile health platform in rural individuals with hypertension (HTN).
The intervention uses a virtual coaching platform to provide health education, monitoring, guidance, and adaptable patient-centered coaching to rural individuals.
The 6-month intervention provides a personalized curriculum to promote HBPM; medication adherence; HTN education; non-pharmacologic strategies for HTN management; preparation for the clinical encounter; and enhanced problem-solving and engagement for rural individuals.
The trial is 12-month duration with visits at baseline, 6, and 12 months.
Individuals with poorly controlled HTN (systolic BP 140-199 or diastolic BP 90-119 mm Hg at 2 ambulatory visits) will be randomized to: (1) intervention, the HBPM coaching intervention and HBPM; or (2) control, smartphone with a general health application (WebMD) and HBPM.
For both intervention and control, summaries of BP measures are provided to clinicians in order to improve HTN management for rural patients.
The primary study outcome is improvement in BP from baseline to 6 months.
The secondary study outcomes are comparison of adherence to antihypertensive medications and patient-reported outcomes in the intervention and usual care arms at 6 and 12 months.
Study Type
Interventional
Enrollment (Estimated)
334
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jared W Magnani, MD
- Phone Number: 4123830611
- Email: magnanij@pitt.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- University of Pittsburgh Medical Center
-
Contact:
- Jared W Magnani, MD
- Phone Number: 412-383-0611
- Email: magnanij@pitt.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- History of uncontrolled hypertension, identified from the electronic health record problem list and an average systolic BP 140-199 or diastolic BP 90-119 mm Hg at 2 ambulatory visits, one of which is within 6 months of study entry
- Prescribed use of one or more antihypertensive agents as identified by the International Society of Hypertension core drug-treatment strategy;
- Residence in one of 48 counties categorized as rural by the Center for Rural Pennsylvania;
- English-speaking at level appropriate for informed consent and study participation;
- No plans to relocate from the area within 12 months of enrollment.
Exclusion Criteria:
- History of malignant HTN (defined by BP >200/120 mm Hg) with or without clinical sequelae;
- Heart failure necessitating hospital admission ≤3 months prior to study inclusion;
- Acute coronary syndrome (defined as at least 2 of the following: chest pain, ischemic electrocardiographic changes, or troponin ≥0.1 ng/mL) ≤3 months prior to study inclusion;
- Planned major surgery, cardiovascular or non-cardiovascular;
- Pregnancy or planned pregnancy within 12 months;
- Presence of non-cardiovascular conditions likely to be fatal within 12 months (e.g., cancer);
- Inability to comprehend the study protocol, defined by failing 3 times to answer correctly a set of questions during consent;
- Institutionalized status (e.g., nursing home, incarceration);
- Inability to operate a smartphone or HBPM device due to sensory or neurocognitive deficit.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
A smartphone-based, interactive coaching application designed to enhance adherence to home-based blood pressure monitoring, provided guidance on blood pressure management, patient-facing education, and assistance with modifying behaviors associated with poor blood pressure control; connected to a wireless blood pressure cuff for accurate blood pressure measurement and automated storage on a digital platform.
All participants in the experimental arm receive a smartphone for the 6-month intervention duration and the home-based blood pressure cuff.
|
A digital application for providing education and support for home-based blood pressure monitoring.
Device for measuring blood pressure at home with blue tooth connectivity for automated collection.
|
Active Comparator: Enhanced usual care
WebMD, a smartphone-based tool for learning about blood pressure and other health conditions.
Enhanced usual care participants receive a wireless blood pressure cuff for accurate blood pressure measurement and automated storage on a digital platform.
All participants in the experimental arm receive a smartphone for the 6-month intervention duration and the home-based blood pressure cuff.
|
Device for measuring blood pressure at home with blue tooth connectivity for automated collection.
Smartphone-based application for health education and/or monitoring.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in systolic and diastolic blood pressure from baseline to 6 months
Time Frame: Baseline, 6 months
|
Change in home-based systolic and diastolic blood pressure from baseline to 6 months between the intervention and usual care arms.
|
Baseline, 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence to antihypertensive medications
Time Frame: Baseline, 6 months
|
Adherence to antihypertensive medication from baseline to 6 months between the intervention and usual care arms using Proportion of Days Covered, ranging from 0 to 100%, where higher values indicate superior medication adherence.
|
Baseline, 6 months
|
Adherence to antihypertensive medications
Time Frame: Baseline, 12 months
|
Adherence to antihypertensive medication from baseline to 12 months between the intervention and usual care arms using Proportion of Days Covered, ranging from 0 to 100%, where higher values indicate superior medication adherence.
|
Baseline, 12 months
|
Patient-Reported Outcomes
Time Frame: Baseline, 6 months
|
Patient-reported outcomes between the intervention and usual care arms at 6 months measured with the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) with distinct assessments of the following: (1) physical function, (2) anxiety, (3) depression, (4) fatigue, (5) sleep, (6) ability to participate in social roles, (7) social role satisfaction, and (8) interference in functioning by pain.
Each domain is scored separately, such that scores for each domain range from 4 (lowest score) to 20 (highest score), where higher scores indicate greater impairment.
|
Baseline, 6 months
|
Patient-Reported Outcomes
Time Frame: Baseline, 12 months
|
Patient-reported outcomes between the intervention and usual care arms at 12 months measured with the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) with distinct assessments of the following: (1) physical function, (2) anxiety, (3) depression, (4) fatigue, (5) sleep, (6) ability to participate in social roles, (7) social role satisfaction, and (8) interference in functioning by pain.
Each domain is scored separately, such that scores for each domain range from 4 (lowest score) to 20 (highest score), where higher scores indicate greater impairment.
|
Baseline, 12 months
|
Self-efficacy for managing medications and treatment
Time Frame: Baseline, 6 months
|
Patient-reported outcomes between the intervention and usual care arms at 6 months measured with the Patient-Reported Outcomes Measurement Information System Self-efficacy for managing medications and treatment, a 10-item instrument, scored from 10 (minimum) to 40 (maximum), where higher scores indicate superior self-efficacy.
|
Baseline, 6 months
|
Self-efficacy or managing medications and treatment
Time Frame: Baseline, 12 months
|
Patient-reported outcomes between the intervention and usual care arms at 12 months measured with the Patient-Reported Outcomes Measurement Information System Self-efficacy for managing medications and treatment, a 10-item instrument, scored from 10 (minimum) to 40 (maximum), where higher scores indicate superior self-efficacy.
|
Baseline, 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 14, 2023
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
June 1, 2027
Study Registration Dates
First Submitted
September 15, 2022
First Submitted That Met QC Criteria
September 15, 2022
First Posted (Actual)
September 21, 2022
Study Record Updates
Last Update Posted (Actual)
August 15, 2023
Last Update Submitted That Met QC Criteria
August 14, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY21120151
- R01HL160749 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The study team will share all of the individual participant data collected during the trial, after deidentification.
IPD Sharing Time Frame
The data will be available 12 months following publication of the primary results of this trial.
IPD Sharing Access Criteria
Researchers who provide a methodologically sound proposal.
Proposals should be directed to the Principal Investigator at magnanij@pittt.edu.
To gain access, data requestors will need to sign a data access agreement.
Data will be provided directly by the study investigators.
Costs associated with producing datasets and analysis will be the responsibility of investigators seeking the data.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaActive, not recruitingImprove Quality of LifeItaly
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Linkoeping UniversityRecruiting
-
South Valley UniversityActive, not recruitingDeterminants of Health-related Quality of Life for Patients After Renal Lithotripsy: PNL Versus RIRSHealth Related Quality of LifeEgypt
-
Region VästmanlandUnknownHealth Related Quality of Life
Clinical Trials on Coaching application
-
Northwestern UniversityCompletedPhysical Activity | Systemic Lupus Erythematosus | SleepUnited States
-
Indonesia UniversityUnknownDiabetes Mellitus, Type 2Indonesia
-
Aga Khan UniversityNot yet recruitingMalnutrition, Child | Malnutrition, InfantPakistan
-
Yonsei UniversityCompleted
-
Northwestern UniversityOmron Healthcare Co., Ltd.Completed
-
Academisch Ziekenhuis MaastrichtEuropean Foundation for the Study of DiabetesCompletedDiabetes Mellitus | Physical Activity | Sedentary Lifestyle | Type2 Diabetes | Aortic Stiffness | Arterial Stiffness | Physical Exercise | Pulse Wave Velocity | Light Intensity Physical Activity | Artery DiseaseNetherlands
-
Mayo ClinicCompletedStress | Anxiety | Leadership | Professional Role | Goals | Well-Being | Physician's Role | Professional Burnout | Development, HumanUnited States
-
Rigshospitalet, DenmarkGilead SciencesCompleted
-
VA Office of Research and DevelopmentAtlanta VA Medical Center; Palo Alto VA Medical CenterRecruitingCardiovascular DiseasesUnited States
-
Queen Mary University of LondonBarts & The London NHS TrustCompletedCardiovascular DiseaseUnited Kingdom